Replies to post #192620 on Biotech Values

[biomaven0]

>>Evidently, the FDA failed to entertain the notion of switching between one generic and another when they formulated the guidelines for bioavailability of small-molecule generics

Well they certainly considered it when tightening the thyroid generic equivalence standard, which is now +-5%. But even that doesn't give full protection because apparently there can still be significant absorption variation between thyroid generics depending on use of acid blockers and the like. That's why many docs still insist on one of the two brand-name thyroid pills.

Peter